Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Bevacizumab in Recurrent Ovarian Cancer
NCT00886691Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Dec 2010
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of everolimus in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Started Dec 2010; status: completed.
02
Drugs
everolimus
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00886691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00886691.